Generic Name: cabotegravir + rilpivirine

Pronunciation: N/A

Abbreviation: CAB LA + RPV LA

Other Market Name: N/A

Drug Class: Single-Tablet Regimens

Company: ViiV Healthcare and Janssen Therapeutics

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cabotegravir + rilpivirine has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.

General Info

Cabotegravir + rilpivirine is an experimental HIV medication. It contains two different types of HIV drugs: one integrase inhibitor and one non-nucleoside reverse transcriptase inhibitor (NNRTI). It is currently in Phase III clinical trials.

Cabotegravir + rilpivirine is a long-acting injectable regimen containing one approved HIV medication Edurant (rilpivirine) and one experimental HIV medication (cabotegravir).


Dosing Info:

This is a long-acting injectable regimen administered every four weeks.

Side Effects


Other Info

Last Reviewed: September 25, 2018